Descartes-08 for Patients With Systemic Lupus Erythematosus

Description

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

Conditions

Systemic Lupus Erythematosus (SLE)

Study Overview

Study Details

Study overview

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

Descartes-08 for Patients With Systemic Lupus Erythematosus

Descartes-08 for Patients With Systemic Lupus Erythematosus

Condition
Systemic Lupus Erythematosus (SLE)
Intervention / Treatment

-

Contacts and Locations

Oceanside

Profound Research LLC, Oceanside, California, United States, 92056

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient must be at least 18 years of age.
  • * Patient must have systemic lupus erythematosus (SLE) at the time of screening.
  • * Active symptoms despite recent or ongoing immunosuppressive therapy with glucocorticoids and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening.
  • * At least one of: anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies detectable at screening as assessed by a CLIA-certified laboratory.
  • * Active severe lupus nephritis, active severe CNS lupus, and/or neurological symptoms of SLE including headache, seizure, psychosis, and organic brain syndrome (a patient with an incidental headache, deemed unrelated to SLE, may re-screen by telephone upon resolution of the headache);
  • * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • * Patient is pregnant or lactating.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cartesian Therapeutics,

Study Record Dates

2026-11-01